Arctic Therapeutics

About:

Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development.

Website: https://www.arctictherapeutics.com/

Top Investors: European Innovation Council

Description:

Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development, as well as sharply reducing the enormous cost and time to bring effective treatments to millions of patients. AT leverages over 20 years of international genomics research, pioneering a novel approach to guide its drug development. The company collaborates closely with The Center for Applied Genomics (CAG) at the Children’s Hospital of Philadelphia to repurpose and develop ground-breaking new medical treatments. A conservative valuation of AT’s pipeline exceeds $100 billion, and the company‘s Alzheimer‘s drug candidate has the potential to become the first cure for dementia, not only treating the disease but preventing it AT's creation was inspired by one of the leading minds in applied genomics, Dr. Hakon Hakonarson, who launched CAG in 2006 and established it as the largest paediatric biobank and genomic database in the world Time Magazine listed Dr. Hakonarson’s autism gene discovery project, reported in Nature in 2009, among the top ten medical breakthroughs of that year. Dr. Hakonarson’ s Nat Med paper on a novel precision-based therapy in lymphatic disorders was awarded among the top 10 clinical/translational papers in 2020 by The Clinical Research Forum. Dr. Hakonarson was recently ranked among “The World’s Most Influential Scientific Minds” by Thomson Reuters, with over 1000 publications and h-index of 171.